News
New open-source interpretation and reporting platform for precision oncology
BC Cancer’s POG team has developed an open source platform for the interpretation and reporting of genomic data in precision oncology.
Martin Krzywinski Makes Music with Pi
Data visualization expert and GSC scientist, Martin Krzywinski, explores how people think and feel about mathematics through music.
Small molecule inhibitor sensitizes lung cancer cells, priming them for death
The GSC’s Gregg Morin Lab characterizes the mechanism of action of a novel small molecule inhibitor and demonstrates its therapeutic potential in lung cancer cells.
Sequencing the Spruce Weevil Genome
Why sequence a weevil? Understanding the insect’s genome could help control one of the most disruptive conifer pests in North America.
New animation makes cancer genomics understandable for everyone
A new animated video that explains cancer genomics in simple language and relatable graphics is useful for many audiences including patients that may want to participate in the program, researchers and practitioners working in the field and those helping to educate others on the topic.
New role for TIRAP protein in the bone marrow microenvironment and preleukemic syndromes
Researchers from the Karsan Lab at the GSC implicate immune-related proteins TIRAP, IFNγ, and Hmgb1 in preleukemic syndrome development and elucidate protein interplay.
Attentive deep learning model, AMPlify, discovers new antimicrobial peptides (AMPs) from sequencing data
The GSC’s Dr. Inanç Birol Lab publishes AMPlify, an attentive deep learning model that helps predict new, putative antimicrobial peptides (AMPs).
Treatment of pediatric chordoma with an immune checkpoint inhibitor slows tumour growth
A POG case report suggests there’s a molecular subset of immunologically hot, INI1-deficient pediatric chordomas and rhabdoid tumours with implications for immune checkpoint inhibitor therapy.
Major scientific and clinical milestones in differentiation therapy for myeloid malignancies
A review of differentiation therapy for myeloid malignancies identifies novel targets for the development of high efficacy drugs with reduced toxicity.